NO20064644L - Kombinert Farmasoytisk sammensetning for inhibisjon av forfall av kognitive funksjoner - Google Patents
Kombinert Farmasoytisk sammensetning for inhibisjon av forfall av kognitive funksjonerInfo
- Publication number
- NO20064644L NO20064644L NO20064644A NO20064644A NO20064644L NO 20064644 L NO20064644 L NO 20064644L NO 20064644 A NO20064644 A NO 20064644A NO 20064644 A NO20064644 A NO 20064644A NO 20064644 L NO20064644 L NO 20064644L
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutical composition
- syndrome
- combined pharmaceutical
- decay
- mental decline
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 230000003920 cognitive function Effects 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000007423 decrease Effects 0.000 abstract 3
- 230000003340 mental effect Effects 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000012440 Acetylcholinesterase Human genes 0.000 abstract 1
- 108010022752 Acetylcholinesterase Proteins 0.000 abstract 1
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000006264 Korsakoff syndrome Diseases 0.000 abstract 1
- 206010034010 Parkinsonism Diseases 0.000 abstract 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000007930 alcohol dependence Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 125000002474 dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000002664 nootropic agent Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/HU2004/000022 WO2005087212A1 (en) | 2004-03-12 | 2004-03-12 | Combined pharmaceutical composition for the inhibition of the decline of cognitive functions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20064644L true NO20064644L (no) | 2006-12-11 |
Family
ID=34957271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20064644A NO20064644L (no) | 2004-03-12 | 2006-10-12 | Kombinert Farmasoytisk sammensetning for inhibisjon av forfall av kognitive funksjoner |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20080021016A1 (pt) |
| EP (1) | EP1727531A1 (pt) |
| JP (1) | JP2007528892A (pt) |
| CN (1) | CN1925849A (pt) |
| AU (1) | AU2004317129A1 (pt) |
| BR (1) | BRPI0418634A (pt) |
| CA (1) | CA2559493A1 (pt) |
| CZ (1) | CZ2006628A3 (pt) |
| EA (1) | EA200601666A1 (pt) |
| HR (1) | HRP20060326A2 (pt) |
| IL (1) | IL177735A0 (pt) |
| IS (1) | IS8547A (pt) |
| MX (1) | MXPA06010384A (pt) |
| NO (1) | NO20064644L (pt) |
| RS (1) | RS20060505A (pt) |
| SK (1) | SK50802006A3 (pt) |
| WO (1) | WO2005087212A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2547730T3 (es) | 2009-07-31 | 2015-10-08 | Cognition Therapeutics, Inc. | Inhibidores del deterioro cognitivo |
| CN104173336B (zh) * | 2010-03-31 | 2018-02-02 | 重庆润泽医药有限公司 | 左旋奥拉西坦在制备预防或治疗认知功能障碍药物中的应用 |
| AU2012212219B2 (en) | 2011-02-02 | 2017-03-23 | Cognition Therapeutics, Inc. | Isolated compounds from turmeric oil and methods of use |
| ITGE20110050A1 (it) * | 2011-04-29 | 2012-10-30 | Marco Zipoli | Alimento, in particolare una bevanda per l'alimentazione umana |
| AU2015210852B2 (en) | 2014-01-31 | 2019-01-24 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| CA3061787A1 (en) | 2017-05-15 | 2018-11-22 | Cognition Therapeutics, Inc. | Compositions for treating neurodegenerative diseases |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8813766D0 (en) * | 1988-06-10 | 1988-07-13 | Efamol Holdings | Essential fatty acid compositions |
| DE4136288A1 (de) * | 1991-11-04 | 1993-05-06 | Troponwerke Gmbh & Co Kg, 5000 Koeln, De | Kombination von calciumantagonisten mit cholinesterase-inhibitoren |
| EP0813411B1 (en) * | 1995-02-15 | 2002-01-23 | Takeda Chemical Industries, Ltd. | Use of vinpocetine derivatives for inhibiting production or secretion of amyloid beta protein |
| US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| GB9820489D0 (en) * | 1998-09-22 | 1998-11-11 | Steiger Malcolm J | Compounds for improved treatment of parkinson's disease |
| US6426097B2 (en) * | 2000-01-28 | 2002-07-30 | Herbaceuticals Inc. | Herbal supplement for cognitive related impairment due to estrogen loss |
| US6335371B1 (en) * | 2000-11-28 | 2002-01-01 | Orion Corporation | Method for inducing cognition enhancement |
| WO2002053147A1 (es) * | 2000-12-29 | 2002-07-11 | Osmotica Corp. | Composicion farmaceutica para el tratamiento de la enfermedad cerebrovascular cognitiva |
| HUP0103017A3 (en) * | 2001-07-18 | 2004-05-28 | Egis Gyogyszergyar Nyilvanosan | Pharmaceutical composition for the treatment of diseases caused by impairment of cognitive functions and its use |
| MXPA04001959A (es) * | 2001-08-30 | 2005-02-17 | Johnson & Johnson | Tratamiento de la demencia y trastornos de la memoria con anticonvulsivantes e. inhibidores de acetilcolinesterasa. |
| DE20203244U1 (de) * | 2002-03-01 | 2002-05-23 | Meins Wolfgang | Pharmazeutische Zusammensetzung zur Prävention der Alzheimerdemenz |
| CN100337628C (zh) * | 2002-08-07 | 2007-09-19 | 王登之 | 治疗痴呆症的尼莫地平口腔崩解片及其制备方法 |
-
2004
- 2004-03-12 WO PCT/HU2004/000022 patent/WO2005087212A1/en active Application Filing
- 2004-03-12 BR BRPI0418634-6A patent/BRPI0418634A/pt not_active IP Right Cessation
- 2004-03-12 CA CA002559493A patent/CA2559493A1/en not_active Abandoned
- 2004-03-12 EP EP04720092A patent/EP1727531A1/en not_active Withdrawn
- 2004-03-12 CZ CZ20060628A patent/CZ2006628A3/cs unknown
- 2004-03-12 US US10/592,461 patent/US20080021016A1/en not_active Abandoned
- 2004-03-12 MX MXPA06010384A patent/MXPA06010384A/es not_active Application Discontinuation
- 2004-03-12 EA EA200601666A patent/EA200601666A1/ru unknown
- 2004-03-12 SK SK5080-2006A patent/SK50802006A3/sk not_active Application Discontinuation
- 2004-03-12 RS YUP-2006/0505A patent/RS20060505A/sr unknown
- 2004-03-12 AU AU2004317129A patent/AU2004317129A1/en not_active Abandoned
- 2004-03-12 JP JP2007502417A patent/JP2007528892A/ja active Pending
- 2004-03-12 CN CNA2004800424056A patent/CN1925849A/zh active Pending
-
2006
- 2006-08-29 IL IL177735A patent/IL177735A0/en unknown
- 2006-09-29 HR HR20060326A patent/HRP20060326A2/xx not_active Application Discontinuation
- 2006-10-03 IS IS8547A patent/IS8547A/is unknown
- 2006-10-12 NO NO20064644A patent/NO20064644L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2559493A1 (en) | 2005-09-22 |
| SK50802006A3 (sk) | 2007-03-01 |
| EA200601666A1 (ru) | 2007-04-27 |
| MXPA06010384A (es) | 2007-03-07 |
| HRP20060326A2 (en) | 2007-02-28 |
| IS8547A (is) | 2006-10-03 |
| US20080021016A1 (en) | 2008-01-24 |
| WO2005087212A1 (en) | 2005-09-22 |
| JP2007528892A (ja) | 2007-10-18 |
| EP1727531A1 (en) | 2006-12-06 |
| CZ2006628A3 (cs) | 2007-01-24 |
| AU2004317129A1 (en) | 2005-09-22 |
| RS20060505A (en) | 2008-09-29 |
| BRPI0418634A (pt) | 2007-05-29 |
| IL177735A0 (en) | 2006-12-31 |
| CN1925849A (zh) | 2007-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20064644L (no) | Kombinert Farmasoytisk sammensetning for inhibisjon av forfall av kognitive funksjoner | |
| BR0314299A (pt) | Derivados de pirrolidona como inibidores de mao-b | |
| CA2883751A1 (en) | Methods of treating alzheimer's disease and pharmaceutical compositions thereof | |
| NO20052739L (no) | CCR5-antagonister som medikamenter | |
| NO20082673L (no) | Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens | |
| BR0211122A (pt) | Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal | |
| NO20045137L (no) | Diketohydrazinderivatforbindelser og legemidler inneholdende forbindelser som aktiv ingrediens | |
| BRPI0409624A (pt) | 2-hidróxi-3-diaminoalcanos de benzamida | |
| EA200870577A1 (ru) | Конденсированные трициклические сульфонамидные ингибиторы гамма-секретазы | |
| BR0312232A (pt) | Inibidores de caspases e seus usos | |
| CA2893468C (en) | Use of vortioxetine and donepezil in the treatment of cognitive impairment | |
| AU2002363182A1 (en) | Smad7 inhibitors for the treatment of cns diseases | |
| ATE367387T1 (de) | Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden | |
| HUP0202745A2 (hu) | Profilaktikus és terápiás szerek szembetegségek kezelésére | |
| NO20070665L (no) | Derivater av 1-fenylalkankarboksylsyrer for behandlingen av neurodegenerative sykdommer | |
| JP2009522257A (ja) | ウイルス感染症治療用薬剤 | |
| EA201070367A1 (ru) | Производное 6-пиримидинилпиримид-4-она | |
| HUP0101224A2 (hu) | Neuraminidáz inhibitor hatású pirrolidinszármazékok és ezeket a vegyületeket tartalmazó gyógyászati készítmények | |
| WO2004058303A3 (en) | Compositions of benzoquinolizine carboxylic acid antibiotic drugs | |
| ATE431147T1 (de) | Mittel zur behandlung des integrationsdysfunktionssyndroms | |
| MX2023011297A (es) | Antagonista del dominio de alfa/beta hidrolasa 6 (abhd6). | |
| BR0209985A (pt) | Composto e método para o tratamento de um paciente | |
| MX2023000437A (es) | Derivado de bencisoxazol. | |
| BR112022014933A2 (pt) | Compostos e composições para uso no tratamento de distúrbios de pele | |
| DK1218401T3 (da) | 4-Benzylaminoquinolin-konjugat med galdesyre og deres heteroanaloger, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |